[Evaluation of bevacizumab combined with XXXX -based regimen as the first-line treatment for @entity1 with metastatic @entity14 ].

@entity1 @entity137 @entity2600 @entity101 @entity548 @entity5 @entity294 @entity787 @entity1398 @entity14 @entity446 @entity1370
OBJECTIVE: To assess the efficacy and safety of bevacizumab plus @entity2600 -based regimen for the first line treatment in metastatic @entity14 (mCRC) @entity1 , and to investigate the correlation between serum @entity5 markers including @entity787 and CA19-9 and response as well as prognosis. METHODS: From May 2007 to July 2008, 67 previously untreated mCRC @entity1 received treatment of IFL (n = 25), IFL plus Bevacizumab (n = 20) or FOLFIRI (n = 22). The treatment continued until disease progression or unacceptable @entity137 . The data were retrospectively analyzed. RESULTS: All @entity1 were evaluable for response, survival and @entity137 analysis. The objective response rate of IFL, IFL plus Bevacizumab or FOLFIRI regimen groups was 16.0% (4/25), 35.0% (7/20) and 18.2% (4/22), respectively (  (2) = 6.026, P = 0.049). The median progression-free survival (PFS) of IFL plus bevacizumab group was 7.5 months, significantly improved as compared with 3.7 months in the IFL group and 4 months in FOLFIRI group (  (2) = 11.97, P = 0.003). Of all 67 cases, the one-year survival rate was 47.0%, two-year survival rate was 27.0%, and the median overall survival (OS) was 13.0 months, with no significant difference among the three treatment groups (  (2) = 3.42, P = 0.18). The serum @entity787 and CA19-9 levels were decreased after treatment, but with no significant difference among the three groups (P > 0.05). The common @entity137 profiles of IFL and FOLFIRI regimens were @entity294 and @entity1398 , while the @entity137 related to bevacizumab was consistent with that documented in previous literature, such as @entity101 , @entity548 , @entity1370 and delayed wound @entity446 . CONCLUSION: The addition of bevacizumab to @entity2600 -based regimen significantly improves the response rate and PFS in first-line treatment for @entity1 with mCRC and its @entity137 is well tolerated.
